Reverse Medical announces initial clinical use of MVP system for peripheral artery embolization

NewsGuard 100/100 Score

Reverse Medical Corporation today announced the initial clinical use of their MVP™ Micro Vascular Plug system for peripheral artery embolization. The device has been granted CE Mark approval to obstruct or reduce the rate of blood flow in the peripheral vasculature.

“the MVP represents a unique advancement for the Interventional Radiologist as being microcatheter deliverable to select distal targets in tortuous anatomy, and is completely re-sheathable for re-positioning if needed, or for procedures where temporary occlusion or flow reduction might be necessary.”

The MVP™ system was introduced May 1st during the 2013 Global Embolization Symposium and Technologies (GEST 2013 - Europe) conference in Prague, Czech Republic, by GEST co-chairman Jafar Golzarian, MD (U. Minnesota, Minneapolis, MN). The clinical cases presented were performed by GEST co-chairman Marc Sapoval, MD PhD and Olivier Pellerin, MD MSc (Hôpital Européen Georges-Pompidou, Paris, France), and Geert Maleux, MD PhD (U. Hospital, Leuven, Belgium). Commenting on their MVP system experiences, Drs. Sapoval and Pellerin agreed "the MVP represents a unique advancement for the Interventional Radiologist as being microcatheter deliverable to select distal targets in tortuous anatomy, and is completely re-sheathable for re-positioning if needed, or for procedures where temporary occlusion or flow reduction might be necessary." Dr. Maleux added, "In addition to the breakthrough deliverability and re-sheathability, the device demonstrated consistent evidence of immediate vessel occlusion." Dr. Golzarian concluded, "The MVP system is a game-changer, has multiple clinical applications for embolization procedures, and based on evidence of immediate occlusion from a single implant, it is cost efficient."

Reverse Medical President & CEO Jeffrey Valko, commented, "Our team continues to innovate at a rapid pace with an expanding range of novel endovascular products. The MVP system represents a platform technology with clinical utility for Peripheral and eventual Neurovascular indications. I'm very enthusiastic about our timing with this technology, as the Embolization market is poised for dramatic growth. We've recently hired a Business Development Director, based in Paris, and we will begin commercialization throughout Europe early third quarter."

Source:

Reverse Medical Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals breakthrough in non-invasive detection of endometrial cancer